Drug
Glycerol phenylbutyrate clinical trials
Also written HPN-100 and RAVICTI.
- studies test it
- 18
- open now
- 2
- in phase 3
- 4
- first study started
- 2005
Keep track of what changes. Save the glycerol phenylbutyrate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 4
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 7
Amgen (11) · Weill Medical College of Cornell University (1) · Technical University of Munich (1) · University of Colorado, Denver (1) · University of Pittsburgh (1) · Scripps Translational Science Institute (1) · Assistance Publique - Hôpitaux de Paris (1) · Kaplan Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses glycerol phenylbutyrate is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related DisordersRecruitingPhase 2Scripps Translational Science InstituteNCT07847918Written as Glycerol Phenylbutyrate
- Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)RecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06887777Written as Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
- PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)CompletedPhase 2Technical University of MunichNCT05983588Written as RAVICTI 1.1 g/ml
- Phenylbutyrate for Monogenetic Developmental and Epileptic EncephalopathyActive, not recruitingEarly Phase 1Weill Medical College of Cornell UniversityNCT04937062Written as Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
- To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)CompletedPhase 4AmgenNCT01257737Written as HPN-100
- Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)CompletedPhase 3AmgenNCT01347073Written as HPN-100
- Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle DisordersCompletedPhase 2AmgenNCT00947544Written as HPN-100
- A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic EncephalopathyCompletedPhase 2AmgenNCT00999167Written as HPN-100
- Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle DisordersCompletedPhase 2AmgenNCT00551200Written as HPN-100
- Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)CompletedPhase 3AmgenNCT00947297Written as HPN-100
- Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle DisordersCompletedPhase 3AmgenNCT00992459Written as HPN-100
- A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle DisordersCompletedPhase 4AmgenNCT02246218Written as RAVICTI
- Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)CompletedPhase 4AmgenNCT03335488Written as RAVICTI
- A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control GroupCompletedPhase 1AmgenNCT00986895Written as HPN-100
- A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)CompletedPhase 1AmgenNCT00977600Written as HPN-100
- Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the BrainCompletedPhase 1University of Colorado, DenverNCT02046434Written as Glycerol Phenylbutyrate
- Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)Status unknownPhase 2/3Kaplan Medical CenterNCT05019417Written as Glycerol Phenylbutyrate 1100 MG/ML
- Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) MutationCompletedPhase 1University of PittsburghNCT01881984Written as Ravicti
Codes
What other systems call glycerol phenylbutyrate · ClinicalTrials.gg INT005993
- MeSH (NLM) C570223glycerol phenylbutyrateOne source NLM
- UNII (FDA) ZH6F1VCV7BGLYCEROL PHENYLBUTYRATEConfirmed FDA, NLM, Wikidata
- RxNorm 1368451Confirmed FDA, Wikidata
- Wikidata Q15322709glycerol phenylbutyrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170031Glycerol PhenylbutyrateOne source FDA
- DrugBank DB08909One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C570223 | glycerol phenylbutyrate | One source NLM |
| UNII (FDA) | ZH6F1VCV7B | GLYCEROL PHENYLBUTYRATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1368451 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15322709 | glycerol phenylbutyrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170031 | Glycerol Phenylbutyrate | One source FDA |
| DrugBank | DB08909 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.